FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

In this GEN webinar, Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, discusses chromatin regulation and epigenetic mechanisms that shape transcriptional responses to ...

Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA ® (vonoprazan ...

Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA ® (vonoprazan ...

We present preclinical data supporting the mechanism of action of detalimogene voraplasmid, which involves immune cell recruitment, tumor microenvironment remodeling and immune training on neoantigens ...

A triple therapy of vonoprazan, amoxicillin and bismuth potassium citrate achieved an eradication rate of just over 90%, similar to that of the standard quadruple therapy, in patients with ...